未经证实:肥大细胞表面结合的IgE有助于慢性自发性荨麻疹(CSU)的发病机理。对CSU来说,特应性是一个诱发因素,其中奥马珠单抗是一种广泛使用的单克隆抗体,通过捕获血清游离IgE来控制荨麻疹症状。然而,血清游离IgE在CSU中的作用尚不清楚。本研究评估了CSU患者血清游离IgE的临床相关性。
UNASSIGNED:本研究纳入了88例CSU患者和76例健康对照(HCs)。通过ImmunoCAPs测量血清总水平和翼状尘螨(Derp)特异性IgE水平。使用新型IgETRAP通过ELISA测量血清游离IgE水平,以及它们与临床参数的关联,包括荨麻疹活动评分(UAS),进行了评估。在23例CSU患者中观察到奥马珠单抗治疗后血清游离和总IgE水平的变化,比较响应者(UAS降低≥50%)和非响应者(降低<50%)。
UNASSIGNED:CSU患者的血清游离/总IgE水平明显高于HC患者,两者呈正相关(rho=0.87,P<0.001)。在CSU患者中,抑制因子的血清游离IgE水平明显高于非抑制因子,WhilenoassociationswerenotedwithUAS,荨麻疹持续时间,或血清ANA或自体血清皮肤试验的结果。此外,奥马珠单抗治疗12个月期间,血清游离IgE水平无显著变化.应答者和非应答者之间的血清游离/总IgE水平或临床参数没有显着差异,而应答者的血清Derp特异性IgE水平及其与血清游离/总IgE水平的比值均高于非应答者(分别为P<0.05)。
UNASSIGNED:这些研究结果表明,血清游离IgE增加可能通过激活肥大细胞参与CSU的发展,尤其是在atopics中。高Derp特异性IgE水平及其与血清游离IgE水平的比率可能是预测CSU中对奥马珠单抗的有利反应的潜在生物标志物。
UNASSIGNED: IgE bound on the surface of mast cells contributes to the pathogenesis of chronic spontaneous urticaria (CSU). Atopy is a predisposing factor for CSU, where omalizumab is a widely used monoclonal antibody to control urticaria symptoms via capturing serum free IgE. However, the role of serum free IgE is not clarified in CSU. The present study evaluated the clinical relevance of serum free IgE in patients with CSU.
UNASSIGNED: Eighty-eight patients with CSU and 76 healthy controls (HCs) were enrolled in this study. Serum total and Dermatophagoides pteronyssinus (Der p)-specific IgE levels were measured by ImmunoCAPs. The serum free IgE levels were measured by ELISA using a novel IgETRAP, and their associations with clinical parameters, including urticaria activity score (UAS), were evaluated. Changes in serum free and total IgE levels after omalizumab treatment were observed in 23 CSU patients in comparison between responders (≥50% reduction in UAS) and non-responders (<50% reduction).
UNASSIGNED: Significantly higher serum free/total IgE levels were noted in CSU patients than in HCs with a positive correlation between the 2 values (rho = 0.87, P < 0.001). Among CSU patients, atopics had significantly higher serum free IgE levels than non-atopics, while no associations were noted with UAS, urticaria duration, or the results of serum ANA or autologous serum skin tests. In addition, there were no significant changes in serum free IgE levels during 12 months of omalizumab treatment. No significant differences were noted in serum free/total IgE levels or clinical parameters between responders and non-responders, while responders have higher serum Der p-specific IgE level and its ratio to serum free/total IgE level than non-responders (P < 0.05, respectively).
UNASSIGNED: These findings suggest that increased serum free IgE may be involved in the development of CSU by activating mast cells, especially in atopics. High Der p-specific IgE level and its ratio to serum free IgE level may be a potential biomarker for predicting favorable responses to omalizumab in CSU.